+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Immunotherapy Drugs Market by Mechanism Of Action, Cancer Type, Treatment Line, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Cancer Immunotherapy Drugs Market by Mechanism Of Action, Cancer Type, Treatment Line, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Cancer Immunotherapy Drugs Market by Mechanism Of Action, Cancer Type, Treatment Line, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010624
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cancer Immunotherapy Drugs Market grew from USD 243.31 billion in 2024 to USD 276.52 billion in 2025. It is expected to continue growing at a CAGR of 13.15%, reaching USD 510.62 billion by 2030.

Unveiling the Transformative Power of Immunotherapy in Cancer Care

In recent years, immunotherapy has emerged as a foundational pillar in the fight against cancer. Unlike traditional cytotoxic approaches, therapies that harness the body’s own immune response have demonstrated unprecedented efficacy across multiple tumor types. From checkpoint inhibitors that release molecular brakes on immune cells to advanced cell‐based treatments that reprogram T cells to seek and destroy malignant targets, these innovations have reshaped clinical paradigms and patient expectations.

As we delve into the transformative potential of immuno‐oncology, this executive summary offers a concise yet thorough overview of critical trends, regulatory influences, and market dynamics. Decision‐makers will gain a clear understanding of the disruptive forces at work, the implications of recent policy shifts, and the strategic segmentation analysis that defines current and future opportunities. This introduction sets the stage for a deep dive into regional landscapes, competitive positioning, and evidence‐based recommendations, ensuring stakeholders are equipped to navigate the evolving terrain of cancer immunotherapy.

Shifting Paradigms Redefining Oncology Treatment

Breakthroughs in molecular biology and clinical trial design have fueled a series of paradigm shifts across oncology. Immune checkpoint inhibitors targeting CTLA-4, PD-1, and PD-L1 receptors have become standard of care for many patients, delivering durable responses where few options existed. Meanwhile, personalized approaches such as chimeric antigen receptor T cell therapies have redefined expectations in hematologic malignancies, illustrating the promise of tailored cellular engineering.

Moreover, the advent of oncolytic viruses, innovative cytokine formulations, and next‐generation cancer vaccines is expanding the therapeutic toolkit. Combinatorial regimens are optimizing efficacy through synergistic mechanisms, while digital biomarkers and advanced diagnostics refine patient selection. Taken together, these transformative shifts underscore a new era in which precision immunomodulation, rather than nonspecific cytotoxicity, drives meaningful clinical outcomes.

Assessing the Impact of US Tariff Changes on Biologics in 2025

The United States’ implementation of revised tariff structures on biologic imports in 2025 has introduced new complexities for manufacturers and care providers. Supply chain costs now carry greater variability, with raw material and finished product levies influencing negotiated pricing and reimbursement strategies. As a result, producers are reassessing global sourcing models, balancing cost containment against the imperative for uninterrupted patient access.

In parallel, regulatory authorities have signaled greater flexibility in tariff mitigation through trade agreements and accelerated review pathways for critical therapies. Payers and hospitals are responding by reinforcing inventory buffers and renegotiating contracts to maintain affordability. Overall, these cumulative tariff impacts necessitate proactive adjustments to manufacturing footprints, contract terms, and market entry tactics to sustain growth trajectories in the competitive immunotherapy arena.

Dissecting Market Dynamics through Multi‐Dimensional Segmentation

A comprehensive segmentation lens reveals the intricate dynamics shaping the immunotherapy market. Mechanistically, offerings range from cancer vaccines designed to prime tumor‐specific immunity and CAR T cell therapies engineered to target defined antigens, to CTLA-4 inhibitors that unleash early T cell activation and cytokine agents that bolster systemic immune responses. Oncolytic viruses selectively infect malignant cells while PD-1 and PD-L1 inhibitors restore immune surveillance, creating a diverse portfolio of actionable modalities.

Cancer type segmentation provides further granularity: therapies are tailored for solid tumors such as bladder, kidney, lung, and melanoma as well as hematologic malignancies divided into leukemia, lymphoma, and multiple myeloma cohorts. Lung cancer treatment differentiates between non‐small cell and small cell subtypes, reflecting distinct molecular drivers. Treatment line considerations-from first through third and beyond-guide adoption curves, while varying administration routes, including intravenous infusions, oral formulations, and subcutaneous injections, cater to patient and provider preferences.

End users span ambulatory care centers, hospitals, and specialty clinics that deliver specialized infusions and manage adverse events, while distribution channels through hospital pharmacies, online dispensaries, and retail outlets ensure broad access. This multi‐dimensional segmentation framework equips stakeholders with the strategic insights needed to allocate resources, optimize product lifecycles, and anticipate shifting demand patterns.

Regional Variances Shaping the Global Immunotherapy Arena

Regional dynamics play a pivotal role in shaping the global immunotherapy landscape. In the Americas, robust R&D infrastructure, streamlined regulatory approvals, and significant venture and public funding accelerate the introduction of novel agents. High levels of insurance coverage and established oncology networks sustain market adoption, although ongoing debates around cost containment and value‐based pricing continue to influence payer decisions.

In Europe, the Middle East and Africa, regulatory harmonization initiatives aim to bridge approval timelines, yet pricing pressures and reimbursement variances pose challenges for innovative therapies. National health technology assessment bodies increasingly demand real‐world evidence to justify premium pricing. Meanwhile, in Asia‐Pacific, rapid expansion of oncology capabilities, supportive government incentives, and growing patient populations are driving demand. However, disparities in infrastructure and access require tailored market entry strategies and partnerships to ensure equitable distribution and sustainable uptake.

Competitive Landscape Spotlight on Industry Leaders Driving Innovation

The competitive landscape is anchored by a cadre of pharmaceutical and biotech leaders advancing immunotherapy pipelines and commercial portfolios. Global giants with established checkpoint inhibitor franchises continue to drive incremental innovation through combination trials and next‐generation molecules. Simultaneously, specialized biotech firms are pioneering cell therapies with unique antigen targets, forging strategic collaborations and licensing agreements to expand manufacturing capacity and geographic reach.

These companies invest heavily in translational research, real‐world evidence generation, and digital health platforms to differentiate offerings and enhance patient adherence. They leverage M&A to consolidate complementary technology platforms, integrate predictive biomarkers into development programs, and secure intellectual property. Through these concerted efforts, industry leaders are optimizing clinical outcomes, reducing time to market, and setting new benchmarks for safety, efficacy, and quality of care.

Strategic Imperatives for Stakeholders to Capitalize on Emerging Opportunities

To capitalize on emerging opportunities, industry leaders must align R&D priorities with evolving clinical needs and regulatory landscapes. Organizations should pursue adaptive trial designs that integrate real‐time data analytics and biomarker stratification, enabling rapid iteration and evidence‐based decision making. Strengthening supply chains through regional manufacturing hubs and strategic partnerships will mitigate tariff impacts and ensure consistent product availability.

In parallel, engaging payers early with robust health economics dossiers and real‐world outcomes data will support favorable reimbursement terms. Embracing patient-centric distribution models, including home infusion and digital monitoring, can enhance adherence and satisfaction. Finally, cultivating cross‐sector alliances-from academic centers to tech innovators-will accelerate translational breakthroughs and position stakeholders at the vanguard of personalized immuno‐oncology.

Robust Research Framework Underpinning the Analysis

This analysis draws on a rigorous research framework integrating primary and secondary insights. Expert interviews with oncology thought leaders, regulatory specialists, and supply chain executives provided firsthand perspectives on clinical developments and market challenges. These qualitative inputs were complemented by an exhaustive review of peer‐reviewed publications, clinical trial registries, patent filings, and policy documents to ensure depth and accuracy.

Quantitative data were validated through triangulation across multiple reputable sources, ensuring consistency and reliability. Analytical tools such as PESTLE and Porter’s Five Forces informed the competitive and regulatory assessments, while segmentation analyses delineated patient and market subgroups. This methodological rigor underlies the strategic recommendations and ensures that findings reflect the latest innovations, policy shifts, and commercial imperatives in cancer immunotherapy.

Concluding Perspectives on the Path Ahead for Immuno‐Oncology

The evolving cancer immunotherapy ecosystem presents both tremendous promise and complex challenges. Breakthrough modalities are reshaping clinical practice, but stakeholders must navigate shifting regulations, pricing pressures, and geographic disparities in access. Through a lens of multi‐dimensional segmentation and regional insight, it becomes clear that success hinges on strategic agility, collaborative innovation, and data‐driven decision making.

Looking ahead, the convergence of precision medicine, digital health, and advanced manufacturing will define the next wave of immunotherapy advances. By proactively addressing emerging barriers and investing in differentiated pipelines, organizations can translate scientific progress into sustainable patient benefit and commercial success. The path forward demands visionary leadership and coordinated action across the entire value chain.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Mechanism Of Action
    • Cancer Vaccines
    • CAR T Cell Therapies
    • CTLA-4 Inhibitors
    • Cytokines
    • Oncolytic Viruses
    • PD-1 Inhibitors
    • PD-L1 Inhibitors
  • Cancer Type
    • Bladder Cancer
    • Hematologic Malignancies
      • Leukemia
      • Lymphoma
      • Multiple Myeloma
    • Kidney Cancer
    • Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Melanoma
  • Treatment Line
    • First Line
    • Second Line
    • Third Line And Beyond
  • Route Of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • End User
    • Ambulatory Care Centers
    • Hospitals
    • Specialty Clinics
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Roche Holding AG
  • AstraZeneca PLC
  • Novartis AG
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • Amgen Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cancer Immunotherapy Drugs Market, by Mechanism Of Action
8.1. Introduction
8.2. Cancer Vaccines
8.3. CAR T Cell Therapies
8.4. CTLA-4 Inhibitors
8.5. Cytokines
8.6. Oncolytic Viruses
8.7. PD-1 Inhibitors
8.8. PD-L1 Inhibitors
9. Cancer Immunotherapy Drugs Market, by Cancer Type
9.1. Introduction
9.2. Bladder Cancer
9.3. Hematologic Malignancies
9.3.1. Leukemia
9.3.2. Lymphoma
9.3.3. Multiple Myeloma
9.4. Kidney Cancer
9.5. Lung Cancer
9.5.1. Non-Small Cell Lung Cancer
9.5.2. Small Cell Lung Cancer
9.6. Melanoma
10. Cancer Immunotherapy Drugs Market, by Treatment Line
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line And Beyond
11. Cancer Immunotherapy Drugs Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
12. Cancer Immunotherapy Drugs Market, by End User
12.1. Introduction
12.2. Ambulatory Care Centers
12.3. Hospitals
12.4. Specialty Clinics
13. Cancer Immunotherapy Drugs Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Americas Cancer Immunotherapy Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Cancer Immunotherapy Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Cancer Immunotherapy Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Merck & Co., Inc.
17.3.2. Bristol-Myers Squibb Company
17.3.3. Roche Holding AG
17.3.4. AstraZeneca PLC
17.3.5. Novartis AG
17.3.6. Johnson & Johnson
17.3.7. Gilead Sciences, Inc.
17.3.8. Amgen Inc.
17.3.9. Pfizer Inc.
17.3.10. Takeda Pharmaceutical Company Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. CANCER IMMUNOTHERAPY DRUGS MARKET MULTI-CURRENCY
FIGURE 2. CANCER IMMUNOTHERAPY DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. CANCER IMMUNOTHERAPY DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. CANCER IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. CANCER IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CANCER IMMUNOTHERAPY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR T CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 61. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 62. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 63. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 64. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 65. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 66. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 70. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 71. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 72. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 111. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 112. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 113. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 114. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 115. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 119. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 120. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 121. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 122. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 123. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 135. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 136. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 137. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 138. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 139. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 143. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 144. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 145. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 146. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 147. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 175. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 176. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 177. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 178. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 179. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 186. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 187. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 191. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 192. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 193. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 194. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 195. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 199. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 200. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 201. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 202. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 203. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 219. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 223. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 224. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 225. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 226. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 227. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 231. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 232. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 233. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 234. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 235. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 247. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 248. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 249. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 250. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 251. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 255. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 256. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 257. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 258. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 259. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 267. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 279. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 280. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 281. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 282. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 283. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 284. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 288. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 289. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 290. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 291. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 292. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 296. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 297. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 298. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 299. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 300. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 301. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 302. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 306. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 307. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 308. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 309. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 310. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA CANCER IMMUNOTHE

Companies Mentioned

The companies profiled in this Cancer Immunotherapy Drugs market report include:
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Roche Holding AG
  • AstraZeneca PLC
  • Novartis AG
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • Amgen Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 276.52 Billion
Forecasted Market Value ( USD ) by 2030 $ 510.62 Billion
Compound Annual Growth Rate13.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cancer Immunotherapy Drug Discovery Outsourcing Market by Service Type, Therapeutic Modality, Workflow Stage, End User - Global Forecast to 2030 - Product Image

Cancer Immunotherapy Drug Discovery Outsourcing Market by Service Type, Therapeutic Modality, Workflow Stage, End User - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From
Immunotherapy Drugs Market Size, Share & Trends Analysis Report by Drug Type (Monoclonal Antibodies, Immunomodulators, Vaccine), Indication (Autoimmune Diseases, Infectious Diseases, Cancer), Region, with Growth Forecasts, 2025-2030 - Product Image

Immunotherapy Drugs Market Size, Share & Trends Analysis Report by Drug Type (Monoclonal Antibodies, Immunomodulators, Vaccine), Indication (Autoimmune Diseases, Infectious Diseases, Cancer), Region, with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Oncology Drugs Market by Drug Class, Route of Administration, Molecule Type, Indication, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Oncology Drugs Market by Drug Class, Route of Administration, Molecule Type, Indication, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Immunotherapy Drugs Market (2025 Edition): Analysis By Indication (Cancer, Autoimmune & Inflammatory Diseases, Other Indications), By Drug Type, By Region, By Country: Market Insights and Forecast (2020-2030) - Product Image

Immunotherapy Drugs Market (2025 Edition): Analysis By Indication (Cancer, Autoimmune & Inflammatory Diseases, Other Indications), By Drug Type, By Region, By Country: Market Insights and Forecast (2020-2030)

  • Report
  • 209 Pages
  • Global
From
Immunotherapy Drugs Market Size and Forecasts 2020-2031: Global and Regional Share, Trends, and Growth Opportunity Analysis by Type, Application, and End-user - Product Image

Immunotherapy Drugs Market Size and Forecasts 2020-2031: Global and Regional Share, Trends, and Growth Opportunity Analysis by Type, Application, and End-user

  • Report
  • 118 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.